Femara heralded as breakthrough in breast cancer
October 28, 2003Sales and Marketing
Compelling new evidence showing Novartis' Femara reduces the risk of breast cancer recurring in patients has been heralded as a …
FDA clears Iressa of safety concerns
October 28, 2003Sales and Marketing
AstraZeneca's lung cancer drug Iressa has gained US approval after an extended review found the drug to be safe, despite …
GSK to remove Seroxat ‘not addictive’ claim
October 28, 2003Sales and Marketing
GlaxoSmithKline is to drop claims on patient information leaflets that its antidepressant Seroxat is not addictive.The admission is to be …
Blair and Milburn braced for foundation trust backlash
October 28, 2003NHS
The Government’s controversial plans to introduce foundation hospitals are on a knife-edge ahead of a Commons vote on the reform …
OTC omeprazole to become Glaxo’s next generation Zantac
October 28, 2003Sales and Marketing
GlaxoSmithKline is poised to launch omeprazole, AstraZeneca's former prescription-only blockbuster Losec as part of its leading over the counter Zantac …
Sanofi upgrades expectations for 2003
October 28, 2003Sales and Marketing
Sanofi-Synthelabo has upgraded its full-year share earnings guidance for 2003, despite its plans to spend more on R&D.In the first …
Concerns over expansion of fast track surgery
October 28, 2003Doctors and health unions have expressed their concerns about the effect of new fast track surgery centres on the rest …
GlaxoSmithKline slashes AIDS drug prices
October 28, 2003Sales and Marketing
GlaxoSmithKline has cut prices of its HIV/AIDS drugs for developing countries by nearly half following intense pressure from campaigners and …
International performance keeps BMS afloat
October 28, 2003Sales and Marketing
International sales of several key drugs helped Bristol-Myers Squibb to minimise the effects of continued US generic competition in the …
Government proposes ‘clinical exceptions’ to A&E targets
October 28, 2003The Government is to modify one of its key waiting times targets after sustained protests about its inability to reflect …
Money Syner buy-out to create UK’s biggest healthcare agency
October 28, 2003Global healthcare communications agency Euro RSCG Life has acquired Money Syner Communications to create what it says will be the …
Pfizer spots potential of Organon atypical antipsychotic
October 28, 2003Pfizer is to co-develop and promote a promising new atypical antipsychotic discovered by Dutch pharma company Organon.Under the terms of …
Latest content
FibroFind appoints Lee Borthwick as CEO
